StageZero Life Sciences Ltd.

TSX:SZLS Stock Report

Mkt Cap: CA$6.4m

We’ve recently updated our valuation analysis.

StageZero Life Sciences Valuation

Is SZLS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SZLS?

Other financial metrics that can be useful for relative valuation.

SZLS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2x
Enterprise Value/EBITDA-1.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does SZLS's PS Ratio compare to its peers?

The above table shows the PS ratio for SZLS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3.5x
MPH Medicure
0.5xn/aCA$12.3m
KNE Kane Biotech
4.4xn/aCA$11.9m
AWKN Awakn Life Sciences
6.3xn/aCA$9.5m
IBT IBEX Technologies
2.8xn/aCA$21.6m
SZLS StageZero Life Sciences
1.4xn/aCA$6.4m

Price-To-Sales vs Peers: SZLS is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (3.5x).

Price to Earnings Ratio vs Industry

How does SZLS's PE Ratio compare vs other companies in the CA Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a48.0%
 n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a48.0%
 n/an/an/a
No more companies

Price-To-Sales vs Industry: SZLS is good value based on its Price-To-Sales Ratio (1.4x) compared to the North American Biotechs industry average (12.3x)

Price to Sales Ratio vs Fair Ratio

What is SZLS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SZLS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.4x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SZLS's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of SZLS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SZLS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SZLS's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

  • Take a look at our analysis of SZLS's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through StageZero Life Sciences regulatory filings.
  • Potentially undervalued companies in the Pharmaceuticals & Biotech industry.